Invitro International (IVRO) fair value: what the stock is really worth
As of Sep 17, 2026: fair value of Invitro International $0.04, price $0.06, upside -40.0%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Invitro International for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.0400 – $0.3900 · the $0.0600 price screens above the $0.0360 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Invitro International in your weekly email
Every Wednesday you see whether Invitro International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
InVitro International, Inc. develops test kits for non-animal testing applications in the United States and internationally.
Show more
InVitro International, Inc. develops test kits for non-animal testing applications in the United States and internationally. Its products include Irritection Assay System, an invitro test, which utilizes the change of relevant macromolecules to predict the ocular and dermal irritancy of chemicals, mixtures, and product formulations; and Corrositex, a non-animal test that determines skin corrosivity based on a biomembrane and chemical detection systems. The company also provides customized technology services for Irritection Assay System installation and testing process, and independent testing laboratory services for irritancy and corrosivity testing requirements, as well as consultation and assistance services. Its products are principally used in cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, hazardous waste, and transportation industries. InVitro International, Inc. was incorporated in 1985 and is headquartered in Placentia, California.
Stock analysis
Invitro International (IVRO) currently trades at $0.0600, while our model-based Fair Value estimate is $0.0360, implying the stock looks roughly 66.7% overvalued today.
Show more
Valuation
Bull case: the Economic Profit group reads highest at a median of $0.0400 per share, and 0 of the 3 models we run sit above the $0.0600 price.
Bear case: the DCF Models group reads lowest at $0.0200, and 3 of the 3 models stay below the price. Evidence for this calculation is low.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Invitro International reported revenue of $793K in FY2023 versus $1.1M in FY2019, a compound −6.8%/yr. Reported net income was $1.6K in FY2023, compounding −61.5%/yr from FY2019.
Key figures
Market cap $1.9M · P/S ratio 2.35 · EPS (TTM) $−0.1100 · Net margin 0.2% · Return on equity 7.1% · Return on assets (EBIT) −0.9% · Operating margin 6.0% · Revenue (TTM) $811K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 60% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −40%, IVRO screens richer than that median.
Fair Value models
Bear $0.0360Fair Value $0.0360Bull $0.0360
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.11/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−7.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.5%
Revenue growth 34 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.4%
’94
’95
’96
’07
’08
’16
’17
’19
’20
’21
’22
’23
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−54.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−54.1%
Dividend (yield on the price)0.0%
Profit margin 2017 to 2023 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → −3%
⚠ Revenue per share shrinking 6.1%/yr over ~32Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside−40% · Below median
Profitability
Return on equity (TTM)7% · Above median
Return on assets2% · Above median
Net margin (TTM)13% · Top 25%
Operating margin (TTM)6% · Below median
Growth and dividend
Revenue growth−13% · Bottom 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/B1.31× · Cheaper than median
P/S (TTM)2.35× · Pricier than median
EV/EBITDA21.3× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 25
PAST (return on equity)28· sector 8
HEALTH (low debt)0· sector 95
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Invitro International Fair Value". https://www.fairvalue-calculator.com/stock/IVRO
Frequently asked questions
Is Invitro International (IVRO) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.0360 versus the last price from Sep 17, 2026 of $0.0600, about −40% upside (overvalued).
What is the fair value of IVRO?
Our model-based fair value for Invitro International is $0.0360 (as of Sep 23, 2026), built from audited fundamentals. Last price (from Sep 17, 2026): $0.0600.
What is the quality score of IVRO?
Invitro International has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Invitro International (IVRO)?
Our model-based price target is the fair value of $0.0360 (as of Sep 23, 2026) from 3 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Invitro International stock forecast for 2026?
Our models put fair value at $0.0360, about −40% upside versus the last price from Sep 17, 2026 of $0.0600 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Invitro International (IVRO)?
Invitro International reported trailing-twelve-month revenue of about $811K (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Invitro International (IVRO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Invitro International it is $0.0360 per share (as of Sep 23, 2026), against a price of $0.0600. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Invitro International stock overvalued or undervalued in 2026?
As of Sep 23, 2026, IVRO trades above its calculated fair value: price $0.0600, fair value $0.0360, a gap of about −40% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IVRO?
No. The price is what the market pays today ($0.0600); the fair value is what the company's own numbers justify ($0.0360). For Invitro International the two are $0.0240 per share apart. That gap is exactly why we show both numbers side by side.
How much is Invitro International worth?
The market values Invitro International at about $1.9M (market capitalisation, as of Sep 23, 2026). Per share that is $0.0600; our models calculate a fair value of $0.0360 per share.
How solid is the balance sheet of Invitro International (IVRO)?
Balance-sheet figures for Invitro International (as of Sep 23, 2026): return on equity 7.1%. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is IVRO from its 52-week high?
Invitro International trades at $0.0600, about 60% below its 52-week high of $0.1500 and 22% above the low of $0.0490 (as of Sep 17, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0360 is for.
Which stocks are comparable to Invitro International?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Invitro International stock attractive at the current price?
The data as of Sep 23, 2026: price $0.0600, calculated fair value $0.0360 (−40%), Quality Score 53/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IVRO calculated?
We run Invitro International through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0360, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Invitro International itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Invitro International (IVRO)?
The latest price we hold is from Sep 17, 2026 and stands at $0.0600. Our model-based fair value is $0.0360, about −40% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Invitro International right now?
The price sits above even our optimistic bull case ($0.0360). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Invitro International
How large is the market capitalisation of Invitro International (IVRO)?
The market capitalisation of Invitro International is $1.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Invitro International (IVRO)?
The price-to-sales ratio of Invitro International is 2.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Invitro International (IVRO)?
Earnings per share at Invitro International are $−0.1100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Invitro International (IVRO)?
The net margin of Invitro International is 0.2% (fiscal year 2023). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Invitro International (IVRO)?
The return on equity (ROE) of Invitro International is 7.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Invitro International (IVRO)?
On an EBIT basis the return on assets of Invitro International is −0.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Invitro International (IVRO)?
The operating margin of Invitro International is 6.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Invitro International (IVRO)?
Revenue at Invitro International is growing −12.9% versus a year earlier (3y avg −10.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Invitro International (IVRO)?
Earnings per share at Invitro International are growing +48.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Invitro International (IVRO) generate?
The free cash flow of Invitro International is −$60.0K (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Invitro International (IVRO) hold?
Invitro International holds more cash than debt, $313K net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Invitro International in the live analysis
One click puts Invitro International on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026